Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588388 · ClinicalTrials.gov registry record · Phase 2
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
A Phase 2 study of Liver Metastases and Extensive-stage Small-cell Lung Cancer, sponsored by Kamya Sankar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 3
- Study locations
NCT05588388: Recruiting Phase 2 study of Liver Metastases and Extensive-stage Small-cell Lung Cancer, sponsored by Kamya Sankar.
NCT05588388 is a Phase 2 study of Liver Metastases and Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Kamya Sankar. The registered enrollment target is 39 participants, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (42% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05588388, a Phase 2 study of Liver Metastases and Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Kamya Sankar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: * In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? * Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: * Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. * Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.
Primary Outcome
Proportion of patients with first occurrence of disease progression or death from any cause (whichever occurs first)
Conditions Studied
Interventions
- DRUG Bevacizumab
Study Locations (3)
Michigan
- V.A. Ann Arbor Healthcare System - Ann Arbor
- University of Michigan - Ann Arbor
California
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-08-11 |
| Est. Completion | 2027-12-28 |
| Phase | Phase 2 |
What NCT05588388 shows while recruiting
NCT05588388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with Liver Metastases appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab is the first listed.
NCT05588388 reports a single indexed study location in Michigan, California.
Frequently Asked Questions
What is clinical trial NCT05588388 about?
NCT05588388 is a clinical study titled "Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases". This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: ...
What is the current status of trial NCT05588388?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-08-11. Estimated completion is 2027-12-28.
What conditions does trial NCT05588388 study?
This clinical trial studies the following conditions: Liver Metastases, Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT05588388?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05588388?
This trial is sponsored by Kamya Sankar, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05588388 being conducted?
This trial has 3 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05588388's enrollment target sits among peer trials
39 12th of 27 higher than 16 of 27 other Liver Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment
RECRUITING · Phase 2
-
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
RECRUITING · Phase 2
-
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
RECRUITING · Phase 2
-
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI